bioAffinity Technologies, Inc. (BIAF)

NASDAQ: BIAF · Real-Time Price · USD

0.5297

-0.0001 (-0.02%)

At close: Aug 6, 2026, 4:00 PM EDT

0.5301

+0.0004 (0.08%)

Pre-market: Aug 7, 2026, 4:50 AM EDT

bioAffinity Technologies Employees

bioAffinity Technologies had 57 employees as of December 31, 2025. The number of employees did not change compared to the previous year.

Employees

57

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

$99,296

Profits / Employee

-$278,596

Market Cap

2.40M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2025	57	0	-
Dec 31, 2024	57	-18	-24.00%
Dec 31, 2023	75	61	435.71%
Dec 31, 2022	14	3	27.27%
Dec 31, 2021	11	-	-

Related Stocks

Company Name	Employees
Burning Rock Biotech	667
MDxHealth	364
XWELL	280
Exagen	220
Precipio	71
Insight Molecular Diagnostics	58
Advanced Biomed	31
Quantum Cyber	13

Employee Rankings

BIAF News

10 days ago - BioAffinity announces publication of clinical review on CyPath Lung - TheFly
10 days ago - bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - Business Wire
15 days ago - BioAffinity Technologies announces collaboration with Pictor - TheFly
15 days ago - bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - Business Wire
4 weeks ago - BioAffinity Technologies’ CyPath Lung diagnostic sales double in Q2 - TheFly
4 weeks ago - bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - Business Wire
6 weeks ago - BioAffinity will present preclinical findings on small interfering RNAs - TheFly
6 weeks ago - bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells - Business Wire